Skip to main content
Top
Published in: Current Pain and Headache Reports 2/2016

01-02-2016 | Other Pain (N Vadivelu and A Kaye, Section Editors)

Chronic Daily Headache: Mechanisms and Principles of Management

Authors: Amy W. Voigt, Harry J. Gould III

Published in: Current Pain and Headache Reports | Issue 2/2016

Login to get access

Abstract

Primary headache is a common malady that is often under-recognized and frequently inadequately managed in spite of the fact that it affects up to 95 % of the population in a lifetime. Many forms of headache, including episodic tension and migraine headaches, if properly diagnosed, are reasonably amenable to treatment, but a smaller, though not insignificant, percent of the population suffer daily from a chronic, intractable form of headache that destroys one’s productivity and quality of life. These patients are frequently seen in neurological practices at a point when treatment options are limited and largely ineffective. In the following review, we will discuss mechanisms drawn from recent studies that address the transition from acute to chronic pain that may apply to the transformation from episodic to chronic daily headaches which may offer opportunities for preempting headache transformation.
Literature
1.
go back to reference Linet MS, Stewart WF, Celentano DD, Ziegler D, Sprecher M. An epidemiologic study of headache among adolescents and young adults. JAMA. 1989;261:2211–6.CrossRefPubMed Linet MS, Stewart WF, Celentano DD, Ziegler D, Sprecher M. An epidemiologic study of headache among adolescents and young adults. JAMA. 1989;261:2211–6.CrossRefPubMed
2.
go back to reference Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41:646–57.CrossRefPubMed Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41:646–57.CrossRefPubMed
3.
go back to reference Silberstein SD, Lipton RB. Chronic daily headache, including transformed migraine, chronic tension-type headache and medication overuse. In: Silberstein SD, Lipton RB, Dalessio DJ, editors. Wolff’s headache and other head pain. 4th ed. New York: Oxford University Press; 2001. p. 247–82. Silberstein SD, Lipton RB. Chronic daily headache, including transformed migraine, chronic tension-type headache and medication overuse. In: Silberstein SD, Lipton RB, Dalessio DJ, editors. Wolff’s headache and other head pain. 4th ed. New York: Oxford University Press; 2001. p. 247–82.
4.
go back to reference Lipton RB. Tracing transformation: chronic migration classification, progression, and epidemiology. Neurology. 2009;72:S3–7.CrossRefPubMed Lipton RB. Tracing transformation: chronic migration classification, progression, and epidemiology. Neurology. 2009;72:S3–7.CrossRefPubMed
5.
go back to reference Raskin NH. Approach to the patient with migraine. Hosp Pract. 1996;31:93–104. Raskin NH. Approach to the patient with migraine. Hosp Pract. 1996;31:93–104.
6.••
go back to reference Evans RW. A rational approach to the management of chronic migraine. Headache. 2013;53:168–76. This is an excellent review of current clinical approaches to treating chronic headaches in terms of medications, office procedures, surgical procedures and non-pharmacologic therapies. CrossRefPubMed Evans RW. A rational approach to the management of chronic migraine. Headache. 2013;53:168–76. This is an excellent review of current clinical approaches to treating chronic headaches in terms of medications, office procedures, surgical procedures and non-pharmacologic therapies. CrossRefPubMed
7.
go back to reference Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the American headache society evidence assessment of migraine pharmacotherapies. Headache. 2015;55:3–20.CrossRefPubMed Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the American headache society evidence assessment of migraine pharmacotherapies. Headache. 2015;55:3–20.CrossRefPubMed
8.
go back to reference Afridi SK, Shields KG, Bhola R, Goadsby PJ. Greater occipital nerve injection in primary headache syndromes: prolonged effects from a single injection. Pain. 2006;122:126–9.CrossRefPubMed Afridi SK, Shields KG, Bhola R, Goadsby PJ. Greater occipital nerve injection in primary headache syndromes: prolonged effects from a single injection. Pain. 2006;122:126–9.CrossRefPubMed
9.
go back to reference Naumann M, So Y, Argoff CE, Childers MK, Dykstra DD, Gronseth GS, et al. Therapeutics and technology assessment subcommittee of the American Academy of Neurology. Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the therapeutics and technology assessment subcommittee of the American academy of neurology. Neurology. 2008;70:1707–14.CrossRefPubMed Naumann M, So Y, Argoff CE, Childers MK, Dykstra DD, Gronseth GS, et al. Therapeutics and technology assessment subcommittee of the American Academy of Neurology. Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the therapeutics and technology assessment subcommittee of the American academy of neurology. Neurology. 2008;70:1707–14.CrossRefPubMed
10.
go back to reference Young WB, Marmura M, Ashkenazi A, Evans RW. Expert opinion: greater occipital nerve and other anesthetic injections for primary headache disorders. Headache. 2008;48:1122–5.CrossRefPubMed Young WB, Marmura M, Ashkenazi A, Evans RW. Expert opinion: greater occipital nerve and other anesthetic injections for primary headache disorders. Headache. 2008;48:1122–5.CrossRefPubMed
11.
go back to reference Saper JR, Silberstein SD, Lake III AE, Winters ME. Double-blind trial of fluoxetine: chronic daily headache and migraine. Headache. 1994;34:497–502.CrossRefPubMed Saper JR, Silberstein SD, Lake III AE, Winters ME. Double-blind trial of fluoxetine: chronic daily headache and migraine. Headache. 1994;34:497–502.CrossRefPubMed
12.
go back to reference Krymchantowski AV, Silva MT, Barbosa JS, Alves LA. Amitriptyline versus amitriptyline combined with fluoxetine in the preventative treatment of transformed migraine: a double-blind study. Headache. 2002;42:510–4.CrossRefPubMed Krymchantowski AV, Silva MT, Barbosa JS, Alves LA. Amitriptyline versus amitriptyline combined with fluoxetine in the preventative treatment of transformed migraine: a double-blind study. Headache. 2002;42:510–4.CrossRefPubMed
13.
go back to reference Tarlaci S. Escitalopram and venlafaxine for the prophylaxis of migraine headache without mood disorders. Clin Neuropharmacol. 2009;32:254–8.CrossRefPubMed Tarlaci S. Escitalopram and venlafaxine for the prophylaxis of migraine headache without mood disorders. Clin Neuropharmacol. 2009;32:254–8.CrossRefPubMed
15.
go back to reference Mathew NT, Ali S. Valproate in the treatment of persistent chronic daily headache. An open label study. Headache. 1991;31:71–4.CrossRefPubMed Mathew NT, Ali S. Valproate in the treatment of persistent chronic daily headache. An open label study. Headache. 1991;31:71–4.CrossRefPubMed
16.
go back to reference Spira PJ, Beran RG. Australian gabapentin chronic daily headache group. Gabapentin in the prophylaxis of chronic daily headache: a randomized, placebo-controlled study. Neurology. 2003;61:1753–9.CrossRefPubMed Spira PJ, Beran RG. Australian gabapentin chronic daily headache group. Gabapentin in the prophylaxis of chronic daily headache: a randomized, placebo-controlled study. Neurology. 2003;61:1753–9.CrossRefPubMed
17.
18.
go back to reference Silberstein SD, Loder E, Forde G, Papadopoulos G, Fairclough D, Greenberg S. The impact of migraine on daily activities: effect of topiramate compared with placebo. Curr Med Res Opin. 2006;22:1021–9.CrossRefPubMed Silberstein SD, Loder E, Forde G, Papadopoulos G, Fairclough D, Greenberg S. The impact of migraine on daily activities: effect of topiramate compared with placebo. Curr Med Res Opin. 2006;22:1021–9.CrossRefPubMed
19.
go back to reference Silberstein SD, Lipton RB, Dodick DW, Topiramate Chronic Migraine Study Group, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache. 2007;47:170–80.CrossRefPubMed Silberstein SD, Lipton RB, Dodick DW, Topiramate Chronic Migraine Study Group, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache. 2007;47:170–80.CrossRefPubMed
20.
go back to reference Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ. TOPMAT-MIG-201(TOP-CHROME) Study Group. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2007;27:814–23.CrossRefPubMed Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ. TOPMAT-MIG-201(TOP-CHROME) Study Group. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2007;27:814–23.CrossRefPubMed
21.
go back to reference Linde K, Rossnagel K. Propranolol for migraine prophylaxis. Cochrane Database Syst Rev. 2004;2:CD003225.PubMed Linde K, Rossnagel K. Propranolol for migraine prophylaxis. Cochrane Database Syst Rev. 2004;2:CD003225.PubMed
22.
23.
go back to reference Nandha R, Singh H. Renin angiotensin system: a novel target for migraine prophylaxis. Indian J Pharm. 2012;44:157–60.CrossRef Nandha R, Singh H. Renin angiotensin system: a novel target for migraine prophylaxis. Indian J Pharm. 2012;44:157–60.CrossRef
24.•
go back to reference Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Quality standards subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78:1337–45. This report provides a comprehensive analysis of published studies from 1999 to 2009 that looked at class I and II articles that listed level A evidence of efficacy for medications used for the prevention of episodic migraine. Guidelines are provided for the use of medications that ideally decrease the frequency and severity of migraine attack, thereby reducing medication overuse and the potential transition to chronic headaches. PubMedCentralCrossRefPubMed Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Quality standards subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78:1337–45. This report provides a comprehensive analysis of published studies from 1999 to 2009 that looked at class I and II articles that listed level A evidence of efficacy for medications used for the prevention of episodic migraine. Guidelines are provided for the use of medications that ideally decrease the frequency and severity of migraine attack, thereby reducing medication overuse and the potential transition to chronic headaches. PubMedCentralCrossRefPubMed
25.
go back to reference Saper JR, Lake III AE, Cantrell DT, Winner PK, White JR. Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study. Headache. 2002;42:470–82.CrossRefPubMed Saper JR, Lake III AE, Cantrell DT, Winner PK, White JR. Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study. Headache. 2002;42:470–82.CrossRefPubMed
26.
go back to reference Tepper SJ, Bigal M, Rapoport A, Sheftell F. Alternative therapies: evidence based evaluation in migraine. Headache Care. 2006;3:57–64.CrossRef Tepper SJ, Bigal M, Rapoport A, Sheftell F. Alternative therapies: evidence based evaluation in migraine. Headache Care. 2006;3:57–64.CrossRef
27.
go back to reference Holland S, Silberstein SD, Freitag F, Dodick DW, Argoff C, Ashman E. Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78:1346–53.PubMedCentralCrossRefPubMed Holland S, Silberstein SD, Freitag F, Dodick DW, Argoff C, Ashman E. Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78:1346–53.PubMedCentralCrossRefPubMed
28.
go back to reference Garza I, Schwedt TJ. Diagnosis and management of chronic daily headache. Semin Neurol. 2010;30:154–66.CrossRefPubMed Garza I, Schwedt TJ. Diagnosis and management of chronic daily headache. Semin Neurol. 2010;30:154–66.CrossRefPubMed
29.
go back to reference Bigal ME, Lipton RB. Clinical course in migraine: conceptualizing migraine transformation. Neurology. 2008;71:848–55.CrossRefPubMed Bigal ME, Lipton RB. Clinical course in migraine: conceptualizing migraine transformation. Neurology. 2008;71:848–55.CrossRefPubMed
30.
go back to reference Kandasamy R, Price TJ. The pharmacology of nociceptor priming. In: Shaible H-G, editor. Pain Control, Handbook of Exper Pharmacol. 2015;227:15–37. Kandasamy R, Price TJ. The pharmacology of nociceptor priming. In: Shaible H-G, editor. Pain Control, Handbook of Exper Pharmacol. 2015;227:15–37.
31.
go back to reference Bigal ME, Rapoport AM, Sheftell FD, Tepper SJ, Lipton RB. Transformed migraine and medication overuse in a tertiary headache centre—clinical characteristics and treatment outcomes. Cephalalgia. 2004;24:483–90.CrossRefPubMed Bigal ME, Rapoport AM, Sheftell FD, Tepper SJ, Lipton RB. Transformed migraine and medication overuse in a tertiary headache centre—clinical characteristics and treatment outcomes. Cephalalgia. 2004;24:483–90.CrossRefPubMed
32.
go back to reference Johnson JL, Hutchinson MR, Williams DB. Medication-overuse headache and opioid-induced hyperalgesia: a review of mechanisms, a neuroimmune hypothesis and a novel approach to treatment. Cephalalgia. 2012;33:52–64.CrossRefPubMed Johnson JL, Hutchinson MR, Williams DB. Medication-overuse headache and opioid-induced hyperalgesia: a review of mechanisms, a neuroimmune hypothesis and a novel approach to treatment. Cephalalgia. 2012;33:52–64.CrossRefPubMed
33.
go back to reference Hutchinson MR, Bland ST, Johnson KW, Rice KC, Maier SF, Watkins LR. Opioid-induced glial activation: mechanisms of activation and implications for opioid analgesia, dependence, and reward. Sci World J. 2007;7:98–111.CrossRef Hutchinson MR, Bland ST, Johnson KW, Rice KC, Maier SF, Watkins LR. Opioid-induced glial activation: mechanisms of activation and implications for opioid analgesia, dependence, and reward. Sci World J. 2007;7:98–111.CrossRef
34.
go back to reference Hutchinson MR, Northcutt AL, Chao LW, Kearney JJ, Zhang Y, Berkelhammer DL, et al. Minocycline suppresses morphine-induced respiratory depression, suppresses morphine-induced reward, and enhances systemic morphine-induced analgesia. Brain Behav Immun. 2008;22:1248–56.PubMedCentralCrossRefPubMed Hutchinson MR, Northcutt AL, Chao LW, Kearney JJ, Zhang Y, Berkelhammer DL, et al. Minocycline suppresses morphine-induced respiratory depression, suppresses morphine-induced reward, and enhances systemic morphine-induced analgesia. Brain Behav Immun. 2008;22:1248–56.PubMedCentralCrossRefPubMed
35.
go back to reference Meng ID, Cao L. From migraine to chronic daily headache: the biological basis of headache transformation. Headache. 2007;47:1251–8.CrossRefPubMed Meng ID, Cao L. From migraine to chronic daily headache: the biological basis of headache transformation. Headache. 2007;47:1251–8.CrossRefPubMed
37.
go back to reference Watkins LR, Hutchinson MR, Rice KC, Maier SF. The “toll” of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting glia. Trends Pharmacol Sci. 2009;30:581–91.PubMedCentralCrossRefPubMed Watkins LR, Hutchinson MR, Rice KC, Maier SF. The “toll” of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting glia. Trends Pharmacol Sci. 2009;30:581–91.PubMedCentralCrossRefPubMed
38.
go back to reference Thalakoti S, Patil VV, Damodaram S, Vause CV, Langford LE, Freeman SE, et al. Neuron-glia signaling in trigeminal ganglion: implications for migraine pathology. Headache. 2007;47:1008–23.PubMedCentralCrossRefPubMed Thalakoti S, Patil VV, Damodaram S, Vause CV, Langford LE, Freeman SE, et al. Neuron-glia signaling in trigeminal ganglion: implications for migraine pathology. Headache. 2007;47:1008–23.PubMedCentralCrossRefPubMed
39.
40.
go back to reference Kandel ER. The molecular biology of memory storage: a dialog between genes and synapses. Biosci Rep. 2004;24:475–522.CrossRefPubMed Kandel ER. The molecular biology of memory storage: a dialog between genes and synapses. Biosci Rep. 2004;24:475–522.CrossRefPubMed
43.
go back to reference Price TJ, Inyang KE. Commonalities between pain and memory mechanisms and their meaning for understanding chronic pain. Prog Mol Biol Transl Sci. 2015;131:409–34.PubMedCentralCrossRefPubMed Price TJ, Inyang KE. Commonalities between pain and memory mechanisms and their meaning for understanding chronic pain. Prog Mol Biol Transl Sci. 2015;131:409–34.PubMedCentralCrossRefPubMed
44.
go back to reference Ledeboer A, Sloane EM, Milligan ED, Frank MG, Mahony JH, Maier SF, et al. Minocycline attenuates mechanical allodynia and proinflammatory cytokine expression in rat models of pain facilitation. Pain. 2005;115:71–83.CrossRefPubMed Ledeboer A, Sloane EM, Milligan ED, Frank MG, Mahony JH, Maier SF, et al. Minocycline attenuates mechanical allodynia and proinflammatory cytokine expression in rat models of pain facilitation. Pain. 2005;115:71–83.CrossRefPubMed
45.
go back to reference Hutchinson MR, Zhang Y, Shridhar M, Evans JH, Buchanan MM, Zhao TX, et al. Evidence that opioids may have toll-like receptor 4 and MD-2 effects. Brain Behav Immun. 2010;24:83–95.PubMedCentralCrossRefPubMed Hutchinson MR, Zhang Y, Shridhar M, Evans JH, Buchanan MM, Zhao TX, et al. Evidence that opioids may have toll-like receptor 4 and MD-2 effects. Brain Behav Immun. 2010;24:83–95.PubMedCentralCrossRefPubMed
46.
go back to reference Ledeboer A, Liu T, Shumilla JA, Mahoney JH, Vijay S, Gross MI, et al. The glial modulatory drug AV411 attenuates mechanical allodynia in rat models of neuropathic pain. Neuron Glia Biol. 2006;2:279–91.CrossRefPubMed Ledeboer A, Liu T, Shumilla JA, Mahoney JH, Vijay S, Gross MI, et al. The glial modulatory drug AV411 attenuates mechanical allodynia in rat models of neuropathic pain. Neuron Glia Biol. 2006;2:279–91.CrossRefPubMed
47.
go back to reference Rolan P, Hutchinson M, Johnson K. Ibudilast: a review of its pharmacology, efficacy and safety in respiratory and neurological disease. Expert Opin Pharmacother. 2009;10:2897–904.CrossRefPubMed Rolan P, Hutchinson M, Johnson K. Ibudilast: a review of its pharmacology, efficacy and safety in respiratory and neurological disease. Expert Opin Pharmacother. 2009;10:2897–904.CrossRefPubMed
48.
go back to reference Barkhof F, Hulst HE, Drulovic J, Uitdehaag BM, Matsuda K, Landin R. MN166-001 investigators. Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant? Neurology. 2010;74:1033–40.CrossRefPubMed Barkhof F, Hulst HE, Drulovic J, Uitdehaag BM, Matsuda K, Landin R. MN166-001 investigators. Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant? Neurology. 2010;74:1033–40.CrossRefPubMed
49.
go back to reference Volfe Z, Dvilansky A, Nathan I. Cannabinoids block release of serotonin from platelets induced by plasma from migraine patients. Int J Clin Pharmacol Res. 1985;5:243–6.PubMed Volfe Z, Dvilansky A, Nathan I. Cannabinoids block release of serotonin from platelets induced by plasma from migraine patients. Int J Clin Pharmacol Res. 1985;5:243–6.PubMed
50.
51.
go back to reference Baron EP. Comprehensive review of medicinal marijuana, cannabinoids, and therapeutic implications in medicine and headache: what a long strange trip it’s been …. Headache. 2015;55:885–916.CrossRefPubMed Baron EP. Comprehensive review of medicinal marijuana, cannabinoids, and therapeutic implications in medicine and headache: what a long strange trip it’s been …. Headache. 2015;55:885–916.CrossRefPubMed
52.
go back to reference Watkins L, Glia MS. A novel drug discovery target for clinical pain. Nat Rev Drug Discov. 2003;2:973–85.CrossRefPubMed Watkins L, Glia MS. A novel drug discovery target for clinical pain. Nat Rev Drug Discov. 2003;2:973–85.CrossRefPubMed
53.
go back to reference Vanast WJ. New daily persistent headaches: definition of a benign syndrome. Headache. 1986;26:317. Vanast WJ. New daily persistent headaches: definition of a benign syndrome. Headache. 1986;26:317.
54.
go back to reference Diaz-Mitoma F, Vanast WJ, Tyrrell DL. Increased frequency of Epstein-Barr virus excretion in patients with new daily persistent headaches. Lancet. 1987;1:411–5.CrossRefPubMed Diaz-Mitoma F, Vanast WJ, Tyrrell DL. Increased frequency of Epstein-Barr virus excretion in patients with new daily persistent headaches. Lancet. 1987;1:411–5.CrossRefPubMed
55.
go back to reference Hamada T, Ohshima K, Ide Y, Sakato S, Takamori M. A case of new daily persistent headache with elevated antibodies to Epstein-Barr virus. Jpn J Med. 1991;30:161–3.CrossRefPubMed Hamada T, Ohshima K, Ide Y, Sakato S, Takamori M. A case of new daily persistent headache with elevated antibodies to Epstein-Barr virus. Jpn J Med. 1991;30:161–3.CrossRefPubMed
56.
go back to reference Santoni JR, Santoni-Williams CJ. Headache and painful lymphadenopathy in extracranial or systemic infection: etiology of new daily persistent headaches. Intern Med. 1993;32:530–2.CrossRefPubMed Santoni JR, Santoni-Williams CJ. Headache and painful lymphadenopathy in extracranial or systemic infection: etiology of new daily persistent headaches. Intern Med. 1993;32:530–2.CrossRefPubMed
57.
go back to reference Li D, Rozen TD. The clinical characteristics of new daily persistent headache. Cephalalgia. 2002;22:66–9.CrossRefPubMed Li D, Rozen TD. The clinical characteristics of new daily persistent headache. Cephalalgia. 2002;22:66–9.CrossRefPubMed
58.
go back to reference Takase Y, Nakano M, Tatsumi C, Matsuyama T. Clinical features, effectiveness of drug-based treatment, and prognosis of new daily persistent headache (NDPH): 30 cases in Japan. Cephalalgia. 2004;24:955–9.CrossRefPubMed Takase Y, Nakano M, Tatsumi C, Matsuyama T. Clinical features, effectiveness of drug-based treatment, and prognosis of new daily persistent headache (NDPH): 30 cases in Japan. Cephalalgia. 2004;24:955–9.CrossRefPubMed
60.
go back to reference Rozen TD. New daily persistent headache. In: Goadsby PJ, Dodick DW, editors. Chronic daily headache for clinicians. 1st ed. Hamilton, Ontario: BC Decker Inc; 2005. p. 209–15. Rozen TD. New daily persistent headache. In: Goadsby PJ, Dodick DW, editors. Chronic daily headache for clinicians. 1st ed. Hamilton, Ontario: BC Decker Inc; 2005. p. 209–15.
61.••
go back to reference Lipton RB. Risk factors for and management of medication-over use headache. Continuum (Minneap Minn). 2015;21:1118–31. This review compares MOH (a secondary headache disorder) to chronic daily headache, and provides guidelines to help the practitioner manage and reduce the risk of medication-overuse headache and limit the development of chronic daily headache. Lipton RB. Risk factors for and management of medication-over use headache. Continuum (Minneap Minn). 2015;21:1118–31. This review compares MOH (a secondary headache disorder) to chronic daily headache, and provides guidelines to help the practitioner manage and reduce the risk of medication-overuse headache and limit the development of chronic daily headache.
62.
go back to reference Krusz JC, Scott V, Belanger J. Intravenous propofol: unique effectiveness in treating intractable migraine. Headache. 2000;40:224–30.CrossRefPubMed Krusz JC, Scott V, Belanger J. Intravenous propofol: unique effectiveness in treating intractable migraine. Headache. 2000;40:224–30.CrossRefPubMed
63.
go back to reference Krusz JC. Intravenous treatment of chronic daily headaches in the outpatient headache clinic. Curr Pain Headache Rep. 2006;10:47–53.CrossRefPubMed Krusz JC. Intravenous treatment of chronic daily headaches in the outpatient headache clinic. Curr Pain Headache Rep. 2006;10:47–53.CrossRefPubMed
64.
65.
go back to reference Obermann M, Katsarava Z. Management of medication-overuse headache. Expert Rev Neurother. 2007;7:1145–55.CrossRefPubMed Obermann M, Katsarava Z. Management of medication-overuse headache. Expert Rev Neurother. 2007;7:1145–55.CrossRefPubMed
66.
go back to reference Mathew NT, Kurman R, Perez F. Drug induced refractory headache—clinical features and management. Headache. 1990;30:634–8.CrossRefPubMed Mathew NT, Kurman R, Perez F. Drug induced refractory headache—clinical features and management. Headache. 1990;30:634–8.CrossRefPubMed
67.
68.
go back to reference Woolf CJ, Walters ET. Common patterns of plasticity contributing to nociceptive sensitization in mammals and Aplysia. Trends Neurosci. 1991;14:74–8.CrossRefPubMed Woolf CJ, Walters ET. Common patterns of plasticity contributing to nociceptive sensitization in mammals and Aplysia. Trends Neurosci. 1991;14:74–8.CrossRefPubMed
69.
go back to reference Bliss TV, Lomo T. Long-lasting potentiation of synaptic transmission in the dentate area of the anaesthetized rabbit following stimulation of the perforant path. J Physiol. 1973;232:331–56.PubMedCentralCrossRefPubMed Bliss TV, Lomo T. Long-lasting potentiation of synaptic transmission in the dentate area of the anaesthetized rabbit following stimulation of the perforant path. J Physiol. 1973;232:331–56.PubMedCentralCrossRefPubMed
70.
go back to reference Cooper JR, Bloom FE, Roth RH. The biochemical basis of neuropharmacology. 6th ed. New York: Oxford University Press; 1991. p. 428–46. Cooper JR, Bloom FE, Roth RH. The biochemical basis of neuropharmacology. 6th ed. New York: Oxford University Press; 1991. p. 428–46.
71.
go back to reference Hebb DO. The organization of behavior. NY: Wiley (Interscience); 1949. Hebb DO. The organization of behavior. NY: Wiley (Interscience); 1949.
72.
go back to reference Ji RR, Kohno T, Moore KA, Woolf CJ. Central sensitization and LTP: do pain and memory share similar mechanisms? Trends Neurosci. 2003;26:696–705.CrossRefPubMed Ji RR, Kohno T, Moore KA, Woolf CJ. Central sensitization and LTP: do pain and memory share similar mechanisms? Trends Neurosci. 2003;26:696–705.CrossRefPubMed
73.
74.
go back to reference Woolf CJ. Central sensitization: uncovering the relation between pain and plasticity. Anesthesiology. 2007;106:864–7.CrossRefPubMed Woolf CJ. Central sensitization: uncovering the relation between pain and plasticity. Anesthesiology. 2007;106:864–7.CrossRefPubMed
76.
go back to reference Pavlov IP. Conditional reflexes. London: Oxford University Press; 1927. Pavlov IP. Conditional reflexes. London: Oxford University Press; 1927.
77.
go back to reference Windholz G. The discovery of the principles of reinforcement, extinction, generalization, and differentiation of conditional reflexes in Pavlov’s laboratories. Pavlov J Biol Sci. 1989;24:35–42.PubMed Windholz G. The discovery of the principles of reinforcement, extinction, generalization, and differentiation of conditional reflexes in Pavlov’s laboratories. Pavlov J Biol Sci. 1989;24:35–42.PubMed
79.
go back to reference Khasar SG, Burkham J, Dina OA, Brown AS, Bogen O, Alessandri-Haber N, et al. Stress induces a switch of intracellular signaling in sensory neurons in a model of generalized pain. J Neurosci. 2008;28:5721–30.PubMedCentralCrossRefPubMed Khasar SG, Burkham J, Dina OA, Brown AS, Bogen O, Alessandri-Haber N, et al. Stress induces a switch of intracellular signaling in sensory neurons in a model of generalized pain. J Neurosci. 2008;28:5721–30.PubMedCentralCrossRefPubMed
81.
go back to reference Melemedjian OK, Asiedu MN, Tillu DV, Peebles KA, Yan J, Ertz N, et al. IL-6- and NGF-induced rapid control of protein synthesis and nociceptive plasticity via convergent signaling to the eIF4F complex. J Neurosci. 2010;30:15113–23.PubMedCentralCrossRefPubMed Melemedjian OK, Asiedu MN, Tillu DV, Peebles KA, Yan J, Ertz N, et al. IL-6- and NGF-induced rapid control of protein synthesis and nociceptive plasticity via convergent signaling to the eIF4F complex. J Neurosci. 2010;30:15113–23.PubMedCentralCrossRefPubMed
82.
go back to reference Melemedjian OK, Asiedu MN, Tillu DV, Sanoja R, Yan J, Lark A, et al. Targeting adenosine monophosphate-activated protein kinase (AMPK) in preclinical models reveals a potential mechanism for the treatment of neuropathic pain. Mol Pain. 2011;7:70.PubMedCentralCrossRefPubMed Melemedjian OK, Asiedu MN, Tillu DV, Sanoja R, Yan J, Lark A, et al. Targeting adenosine monophosphate-activated protein kinase (AMPK) in preclinical models reveals a potential mechanism for the treatment of neuropathic pain. Mol Pain. 2011;7:70.PubMedCentralCrossRefPubMed
83.
go back to reference Melemedjian OK, Tillu DV, Asiedu MN, Mandell EK, Moy JK, Blute VM, et al. BDNF regulates atypical PKC at spinal synapses to initiate and maintain a centralized chronic pain state. Mol Pain. 2013;9:12.PubMedCentralCrossRefPubMed Melemedjian OK, Tillu DV, Asiedu MN, Mandell EK, Moy JK, Blute VM, et al. BDNF regulates atypical PKC at spinal synapses to initiate and maintain a centralized chronic pain state. Mol Pain. 2013;9:12.PubMedCentralCrossRefPubMed
84.
go back to reference Price TJ, Dussor GAMPK. An emerging target for modification of injury-induced pain plasticity. Neurosci Lett. 2013;557(Pt A):9–18.CrossRefPubMed Price TJ, Dussor GAMPK. An emerging target for modification of injury-induced pain plasticity. Neurosci Lett. 2013;557(Pt A):9–18.CrossRefPubMed
85.
go back to reference Russe OQ, Möser CV, Kynast KL, King TS, Stephan H, Geisslinger G, et al. Activation of the AMP-activated protein kinase reduces inflammatory nociception. J Pain. 2013;14:1330–40.CrossRefPubMed Russe OQ, Möser CV, Kynast KL, King TS, Stephan H, Geisslinger G, et al. Activation of the AMP-activated protein kinase reduces inflammatory nociception. J Pain. 2013;14:1330–40.CrossRefPubMed
86.
87.
go back to reference Ferrari LF, Bogen O, Levine JD. Role of nociceptor αCaMKII in transition from acute to chronic pain (hyperalgesic priming) in male and female rats. J Neurosci. 2013;33:11002–11.PubMedCentralCrossRefPubMed Ferrari LF, Bogen O, Levine JD. Role of nociceptor αCaMKII in transition from acute to chronic pain (hyperalgesic priming) in male and female rats. J Neurosci. 2013;33:11002–11.PubMedCentralCrossRefPubMed
88.
go back to reference Rivat C, Bollag L, Richebé P. Mechanisms of regional anaesthesia protection against hyperalgesia and pain chronicization. Curr Opin Anaesthesiol. 2013;26:621–5.CrossRefPubMed Rivat C, Bollag L, Richebé P. Mechanisms of regional anaesthesia protection against hyperalgesia and pain chronicization. Curr Opin Anaesthesiol. 2013;26:621–5.CrossRefPubMed
89.
go back to reference Ashkenazi A, Benlifer A, Korenblit J, Silberstein SD. Zonisamide for migraine prophylaxis in refractory patients. Cephalalgia. 2006;26:1199–202.CrossRefPubMed Ashkenazi A, Benlifer A, Korenblit J, Silberstein SD. Zonisamide for migraine prophylaxis in refractory patients. Cephalalgia. 2006;26:1199–202.CrossRefPubMed
90.
go back to reference Spengos K, Theleritis C, Paparrigopoulos T. Memantine and NMDA antagonism for chronic migraine: a potentially novel therapeutic approach? Headache. 2008;48:284–6.CrossRefPubMed Spengos K, Theleritis C, Paparrigopoulos T. Memantine and NMDA antagonism for chronic migraine: a potentially novel therapeutic approach? Headache. 2008;48:284–6.CrossRefPubMed
91.
go back to reference Bigal M, Rapoport A, Sheftell F, Tepper D, Tepper S. Memantine in the preventive treatment of refractory migraine. Headache. 2008;48:1337–42.CrossRefPubMed Bigal M, Rapoport A, Sheftell F, Tepper D, Tepper S. Memantine in the preventive treatment of refractory migraine. Headache. 2008;48:1337–42.CrossRefPubMed
92.
go back to reference Wang ZJ, Wang LX. Phosphorylation: a molecular switch in opioid tolerance. Life Sci. 2006;79:1681–91.CrossRefPubMed Wang ZJ, Wang LX. Phosphorylation: a molecular switch in opioid tolerance. Life Sci. 2006;79:1681–91.CrossRefPubMed
93.
go back to reference Cavallo JS, Hamilton BN, Farley J. Behavioral and neural bases of extinction learning in Hermissenda. Front Behav Neurosci. 2014;8(277):1–17. Cavallo JS, Hamilton BN, Farley J. Behavioral and neural bases of extinction learning in Hermissenda. Front Behav Neurosci. 2014;8(277):1–17.
94.
go back to reference Cavallo JS, Hamilton BN, Farley J. In vitro extinction learning in Hermissenda: involvement of conditioned inhibition molecules. Front Behav Neurosci. 2014;8(354):1–24. Cavallo JS, Hamilton BN, Farley J. In vitro extinction learning in Hermissenda: involvement of conditioned inhibition molecules. Front Behav Neurosci. 2014;8(354):1–24.
95.
go back to reference Hüllemann P, Shao YQ, Manthey G, Binder A, Baron R. Central habituation and distraction alter C-fibre-mediated laser-evoked potential amplitudes. Eur J Pain. 2015. doi:10.1002/ejp.735. Hüllemann P, Shao YQ, Manthey G, Binder A, Baron R. Central habituation and distraction alter C-fibre-mediated laser-evoked potential amplitudes. Eur J Pain. 2015. doi:10.​1002/​ejp.​735.
96.
go back to reference Shealy CN. Guided imagery, mindful meditation, and hypnosis for pain management. Pract Pain Manage. 2015;15:29–34. Shealy CN. Guided imagery, mindful meditation, and hypnosis for pain management. Pract Pain Manage. 2015;15:29–34.
97.
go back to reference Trevelyan EG, Turner WA, Robinson N. Acupuncture for the treatment of phantom limb pain in lower limb amputees: study protocol for a randomized controlled feasibility trial. Trials. 2015;16(158):1–8. Trevelyan EG, Turner WA, Robinson N. Acupuncture for the treatment of phantom limb pain in lower limb amputees: study protocol for a randomized controlled feasibility trial. Trials. 2015;16(158):1–8.
Metadata
Title
Chronic Daily Headache: Mechanisms and Principles of Management
Authors
Amy W. Voigt
Harry J. Gould III
Publication date
01-02-2016
Publisher
Springer US
Published in
Current Pain and Headache Reports / Issue 2/2016
Print ISSN: 1531-3433
Electronic ISSN: 1534-3081
DOI
https://doi.org/10.1007/s11916-016-0542-3

Other articles of this Issue 2/2016

Current Pain and Headache Reports 2/2016 Go to the issue

Childhood and Adolescent Headache (S Evers, Section Editor)

Lifestyle Factors and Migraine in Childhood

Other Pain (N Vadivelu and A Kaye, Section Editors)

New Labor Pain Treatment Options

Psychological and Behavioral Aspects of Headache and Pain (D Buse, Section Editor)

Behavioral Weight Loss Treatments for Individuals with Migraine and Obesity

Psychological and Behavioral Aspects of Headache and Pain (D Buse, Section Editor)

Model and Processes of Acceptance and Commitment Therapy (ACT) for Chronic Pain Including a Closer Look at the Self

Secondary Headache (M Robbins, Section Editor)

Headache in Intracranial and Cervical Artery Dissections

Childhood and Adolescent Headache (S Evers, Section Editor)

Chronic Migraine in Children and Adolescents